Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Scott on Connect MDS and AML: A Disease Registry

April 30th 2015

Bart L. Scott, assistant member, clinical research division, Fred Hutchinson Cancer Research Center, discusses a new registry that will collect data from patients with MDS.

Dr. Garcia-Manero on Rigosertib in Patients with High-Risk MDS After Failure of Hypomethylating Agents

April 30th 2015

Guillermo Garcia-Manero, MD, chief, Section of Myelodysplastic Syndromes, deputy chair, Translational Research, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the multikinase inhibitor rigosertib in patients with MDS who have failed hypomethylating agents.

Sotatercept Effectively Treats Anemia in MDS and Non-Proliferative CMML

April 30th 2015

The first-in-class activin receptor antagonist sotatercept stimulated erythropoiesis in nearly half of patients with MDS and non-proliferative CMML following failure on erythropoiesis-stimulating agents.

Supportive Care Is Key in MDS Treatment

April 28th 2015

Interview with Thomas Prebet MD, PhD, in advance of the 2015 International MDS Symposium, on topics related to supportive care in MDS and iron chelation therapy.

Ibrutinib and Idelalisib Continue to Impress in CLL, May Eventually Replace Chemotherapy for Some Patients

April 28th 2015

To gain further insight into the impact of ibrutinib and idelalisib, as well as other emerging therapies and treatment strategies in CLL, OncLive sat down with Steven Coutre, MD, at the AACR meeting,

CAR T-Cell Therapy Surpasses 90% Complete Remission Rate in Pediatric ALL

April 24th 2015

The chimeric antigen receptor T-cell therapy JCAR017 elicited a 91% complete remission rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.

Ibrutinib Response Rates Improve With Longer Follow-Up in CLL

April 24th 2015

Single-agent ibrutinib demonstrated an overall response rate of 91%, including a complete response rate of 14%, in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Inotuzumab Ozogamicin Improves Response Rates Versus Chemotherapy in Phase III ALL Study

April 23rd 2015

Treatment with the antibody-drug conjugate inotuzumab ozogamicin significantly extended complete hematologic remission rates compared with chemotherapy for adult patients with relapsed or refractory CD22-positive acute lymphoblastic leukemia,

Vitamin D Deficient Follicular Lymphoma Patients Experience Higher Relapse Risk

April 22nd 2015

Low vitamin D levels prior to treatment may be linked to risk of relapse or death for patients with follicular lymphoma.

FDA Grants Priority Review to Brentuximab Vedotin Consolidation in Hodgkin Lymphoma

April 20th 2015

The FDA has granted a priority review to the antibody-drug conjugate brentuximab vedotin as a consolidation therapy following autologous stem cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression.

Breakthrough T-Cell Therapy Halts EBV-Associated Lymphoproliferative Disorders

April 19th 2015

Infusions of Epstein-Barr virus (EBV)–specific cytotoxic T lymphocytes from healthy donors led to high response rates and significant extensions in overall survival for patients with rituximab-refractory EBV–associated lymphoproliferative disorders.

Dr. Komrokji on Optimizing MDS Management

April 14th 2015

Rami S. Komrokji, MD, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses optimizing the management of treatment for myelodysplastic syndrome (MDS).

Novel Agents Set to Revolutionize NHL Treatment

April 13th 2015

M. Yair Levy, MD, discussed the impact of non-chemotherapeutic agents on the treatment of patients with NHL in an interview with OncLive.

Dr. Vij on Tumor Bank for Multiple Myeloma at Siteman Cancer Center

April 9th 2015

Ravi Vij, MD, associate professor, medicine, Division of Oncology, Section of Bone Marrow Transplant, Siteman Cancer Center, discusses the institution's tumor banking initiative for next-generation sequencing in multiple myeloma.

Three-Drug Combos, Immunotherapy Mark Future of Myeloma Management

April 8th 2015

Sundar Jagannath, MD, discusses the latest research advances in myeloma, and how these steps will impact the future treatment paradigm for the disease.

Dr. Gascoyne on Predictive Biomarker Research in Lymphomas

April 8th 2015

Randy Gascoyne, MD, research director, Centre for Lymphoid Cancers at the BC Cancer Agency, discusses the growth of predictive biomarker research in follicular lymphoma and other malignancies.

ASH Report Carves Out a New Role for Hematologists

April 3rd 2015

The American Society of Hematology is calling for the creation of a new clinical hematology specialty that would be based in a medical center or health system and would focus primarily on patients with benign blood disorders, while also helping to manage genomic testing and pathways-centered care.

FDA Approves New Oral Formulation of Deferasirox

March 31st 2015

The FDA has granted an accelerated approval to an oral formulation of deferasirox (Jadenu) for the treatment of patients aged 2 and older with chronic iron overload due to multiple blood transfusions.

MCL Patients Progressing on Ibrutinib Respond Poorly to Salvage Therapy

March 30th 2015

Patients with mantle cell lymphoma who develop ibrutinib resistance are unlikely to respond favorably to salvage chemotherapy.

On the Brink of Change

March 26th 2015

The profound changes under way in the treatment of leukemia were among the highlights captured in our coverage of the 19th Annual International Congress on Hematologic Malignancies:® Focus on Leukemias, Lymphomas, and Myeloma.

NEXT PAGE
PREVIOUS PAGE